Helping patients reclaim a life of possibility
At the end of March, the Committee for Medicinal Products for Human Use (CHMP) announced two positive recommendations for new ways of administering the existing myeloma drugs daratumumab and isatuximab. Both drugs are monoclonal antibodies used in the treatment of myeloma. Both CHMP recommendations focus on subcutaneous injection, where a medication is injected into the…
Bosnia and Herzegovina marks myeloma awareness month We are delighted to share an update from our member organisation in Bosnia and Herzegovina, who marked Myeloma Action Month with a series of meaningful activities in March. On 26 March, they organised a professional meeting in Tuzla, bringing together over 50 participants including haematologists, healthcare professionals, patients…
At the MPE Annual General Meeting on Tuesday, 31 March, we were pleased to welcome four new member organisations into the MPE community and to confirm the results of our board elections. Together, they represent the continued growth and diversity of the myeloma and amyloidosis patient community across Europe. New members Hellenic Multiple Myeloma Patient…
The French Prime Minister Recognizes AF3M as a Public Interest Association MPE member, The French Association of Myeloma Patients (AF3M) has been officially recognized as a Public Interest Association (Association Reconnue d’Utilité Publique) by decree dated 5 March 2026 and published in the French Republic Official Journal on 7 March 2026. This prestigious status is…
Launch of new myeloma patient support group, Myeloma Forward, in Northern Ireland On Monday, 23 March a new myeloma patient support group, called Myeloma Forward, launched in Belfast, Northern Ireland (NI). Myeloma Forward will hold bi-monthly meetings where speakers talk about some aspect of living with myeloma and share experiences and stories, providing peer support…
MPE team members Kate Morgan (Co-CEO) and Barbara Leonardi (President) visited a private plasma donation centre in Vienna, Austria. Plasma donations are needed from people to produce immunoglobulin replacement therapy (you might hear it called IVIG) which is used in myeloma to reduce the risk of infection. It is of interest to MPE because myeloma…
Myeloma Patients Europe (MPE) will hold a webinar on the generics market in Europe and implications for cancer treatment and care on Monday 30th March from 17:00 – 18:30 CET. A generic medicine has the same active ingredient as a branded medicine and can be produced after the patent for the branded medicine expires. For…
Myeloma has always been an incurable cancer which is becoming increasingly chronic with treatment advances and access. Whilst the community remains cautious talking about myeloma as a curable cancer there is optimism amongst industry experts.The Myeloma Cure Summit was an event organised by the International Myeloma Society in Miami, Florida, USA from 20 – 21 February 2026.…